LB Pharmaceuticals
LBRX
114 hedge funds and large institutions have $966M invested in LB Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 41 increasing their positions, 13 reducing their positions, and 3 closing their positions.
1,300% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 3
215% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 13
147% more capital inflows, than outflows
Capital inflows: $79.9M | Capital outflows: $32.3M
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
48% more funds holding
Funds holding: 77 → 114 (+37)
5.39% more ownership
Funds ownership: 98.38% → 103.77% (+5.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boothbay Fund Management
New York
|
+$8.1M |
| 2 |
BlackRock
New York
|
+$7.74M |
| 3 |
Goldman Sachs
New York
|
+$6.25M |
| 4 |
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$5.98M |
| 5 |
Millennium Management
New York
|
+$3.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCG Crossover Management
Palo Alto,
California
|
-$11.5M |
| 2 |
Logos Global Management
San Francisco,
California
|
-$9.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.9M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.53M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$1.12M |
LBRX Hedge Fund Activity: Q2 2026 in Review
114 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in LB Pharmaceuticals (LBRX) for Q2 2026, worth a combined $966M — up 39% from $692M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new LBRX positions and 3 closed out — a net gain of 39 holders — while 41 added to existing stakes and 13 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $8.1M. The largest seller was TCG Crossover Management, cutting an estimated $11.5M.
- 114 institutional investors held LB Pharmaceuticals (LBRX) as of Q2 2026, up from 77 in Q1 2026.
- Funds reported $966M of LB Pharmaceuticals stock for Q2 2026, up 39% quarter-over-quarter.
- 42 funds opened new LB Pharmaceuticals positions in Q2 2026 and 3 closed out, a net change of +39 holders.
- The largest LB Pharmaceuticals buyer in Q2 2026 was Boothbay Fund Management, an estimated $8.1M added.
- The largest LB Pharmaceuticals seller in Q2 2026 was TCG Crossover Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2026.